{"schema_version":"1.0","type":"article","title":"這些中型 Biotech，正在把「重磅炸彈藥物」從夢想變成現金流","url":"https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow.md","lang":"zh-Hant","date":"2026-05-22","publish_at":"2026-05-22T10:30:00+08:00","updated_at":"2026-05-22","category":"商業分析系列","topic":"商業分析系列","tags":["Dcard","免費文章","Alzheimer","GLP-1","CNS","FDA","藥華藥","BESREMi"],"summary":"在很長一段時間裡，製藥業的 blockbuster drug，似乎是大型藥廠的專屬勳章。","key_points":[],"facts":[],"sections":["01｜ 中型 Biotech 的觀察重點，正在從臨床節點轉向商業兌現","02｜🧠 Axsome：Auvelity 從憂鬱症，走向 Alzheimer’s agitation 的大市場","03｜🧬 TG Therapeutics：Briumvi 在多發性硬化成熟市場中撕開缺口","04｜🧪 Neurocrine：Crenessity 讓罕見內分泌疾病也能長出 blockbuster 潛力","05｜🫀 Madrigal：Rezdiffra 把 MASH 從概念市場推進真實收入","06｜🫁 Insmed：Brinsupri 讓被忽略的慢性呼吸道疾病變成十億美元機會","07｜ Harmony：Wakix 用多年商業化執行，走向十億美元品牌","08｜Ascendis：Yorvipath 證明罕見內分泌疾病也能接近重磅高度","09｜這些產品共同告訴我們：blockbuster 不只是臨床成功，而是商業系統成功","10｜ 台灣生技股？"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia","source":"FDA","date":"","url":""},{"title":"The U.S. Food and Drug Administration today approved an expanded use for Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets to treat agitation associated with dementia due to Alzheimer’s disease in adults.","source":"","date":"","url":""},{"title":"www.fda.gov","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"Axsome increases Auvelity's peak sales projection to $8B","source":"","date":"","url":""},{"title":"A few days after gaining an FDA expansion for Auvelity to treat Alzheimer’s disease agitation, Axsome has projected its peak sales to reach $8 billion","source":"","date":"","url":""},{"title":"www.fiercepharma.com","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-neurocrine-biosciences-genetic-disorder-drug-2024-12-13/","source":"","date":"","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-neurocrine-biosciences-genetic-disorder-drug-2024-12-13/"},{"title":"www.reuters.com","source":"","date":"","url":""},{"title":"[6]:","source":"","date":"","url":""},{"title":"[7]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-first-drug-fatty-liver-disease-nash-2024-03-14/","source":"","date":"","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-first-drug-fatty-liver-disease-nash-2024-03-14/"},{"title":"www.reuters.com","source":"","date":"","url":""},{"title":"[8]:","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：這些中型 Biotech，正在把「重磅炸彈藥物」從夢想變成現金流","url":"https://drugnews.com.tw/assets/articles/mid-size-biotech-blockbuster-cashflow/dcard-01.webp"},{"alt":"Dcard 原圖：這些中型 Biotech，正在把「重磅炸彈藥物」從夢想變成現金流","url":"https://drugnews.com.tw/assets/articles/mid-size-biotech-blockbuster-cashflow/dcard-02.png"},{"alt":"Dcard 原圖：這些中型 Biotech，正在把「重磅炸彈藥物」從夢想變成現金流","url":"https://drugnews.com.tw/assets/articles/mid-size-biotech-blockbuster-cashflow/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/mid-size-biotech-blockbuster-cashflow/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-22）。這些中型 Biotech，正在把「重磅炸彈藥物」從夢想變成現金流。https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-05-22-mid-size-biotech-blockbuster-cashflow-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}